Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Journal article
Yang H. et al, (2021), Cell reports, 35
Characterizing Hepatitis C Virus-Specific CD4+ T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure.
Journal article
Hartnell F. et al, (2020), Hepatology (Baltimore, Md.), 72, 1541 - 1555
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Journal article
Esposito I. et al, (2020), Science translational medicine, 12
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Journal article
Fidler S. et al, (2020), Lancet (London, England), 395, 888 - 898
A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.
Journal article
Hancock G. et al, (2019), Scientific reports, 9
Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients
Conference paper
Hoffmann M. et al, (2019), HIV MEDICINE, 20, 36 - 36
Lessons from the Research in Viral Eradication of Reservoirs (RIVER) study: Impact of a therapeutic vaccine targeting conserved HIV epitopes on T cell function in treated primary infection
Conference paper
Kopycinski J. et al, (2019), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 22, 20 - 21
Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection.
Journal article
Zilber E. et al, (2019), AIDS (London, England), 33, 1253 - 1256
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Journal article
Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80
MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans
Conference paper
Esposito I. et al, (2019), JOURNAL OF HEPATOLOGY, 70, E3 - E4
MS-Rescue: A Computational Pipeline to Increase the Quality and Yield of Immunopeptidomics Experiments.
Journal article
Andreatta M. et al, (2019), Proteomics, 19
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
Journal article
López-Camacho C. et al, (2018), Nature Communications, 9
Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers
Journal article
Rosás-Umbert M. et al, (2018), Journal of Virology, 93
A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a "Kick-and-Kill" approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial
Conference paper
Fidler S. et al, (2018), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 21, 155 - 155
LBP-002: Novel ImmTAV molecules for the treatment of HBV
Conference paper
(2018), Journal of Viral Hepatitis, 25, 194 - 194
CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA
Journal article
Martin GE. et al, (2018), Frontiers in Immunology, 9
Therapeutic HPV vaccines
Journal article
Hancock G. et al, (2018), Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 59 - 72
A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Journal article
Hartnell F. et al, (2018), Frontiers in immunology, 9
Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Journal article
Yang H. et al, (2018), Frontiers in immunology, 9
Pathophysiology of ischaemic heart disease
Journal article
Pocock MO. et al, (2017), Current Opinion in HIV and AIDS, 12, 548 - 553